Science News
Discover the news and inspiring materials from the world of biotechnology.
MabionCD20 development path in dialogue with the FDA
Mabion and Oddifact have submitted documentation to the FDA, including a request for a Type B Pre-IND meeting concerning the planned development of MabionCD20 in immune thrombocytopenia. The regulatory interaction is intended to address the preclinical program, CMC strategy and clinical development pathway, supporting define the requirements for potential progression toward clinical trials.
Learn more
Mabion receives the Responsible Entrepreneur Certificate
Mabion has been awarded the Responsible Entrepreneur Certificate in recognition of its commitment to environmental protection, sustainability and corporate social responsibility.
Learn more
New ranibizumab biosimilar enters the market
Ranibizumab is one example of a biologic drug that has achieved market success. Let’s trace the transformation of retinal disease treatment from the landmark 2006 approval of Lucentis to the current competitive era defined by more affordable biosimilar alternatives.
Learn more
Izenivetmab is available for veterinary use in the EU
Izenivetmab is a long-acting monoclonal antibody therapy made by Zoetis to treat joint pain from osteoarthritis in dogs. This medicine has received regulatory approvals in the European Union, the United Kingdom and Canada.
Learn more
Mabion and KriSan Biotech sign Agreement to strengthen next-generation ADC services
The Master Service Agreement between Mabion and KriSan Biotech was signed at the BIO Asia–Taiwan by Rongjin Lin, Chairman of KriSan Biotech Co., Ltd., and Gregor Kawaletz, CEO of Mabion, in the presence of representatives from the Ministry of Foreign Affairs of the Republic of Poland and the Ministry of Economic Affairs (Taiwan).
Learn more
KRAS vaccine is an effective treatment for pancreatic cancer
Experimental KRAS vaccine safely generated durable immune responses in people at high risk of developing pancreatic cancer. The study provides proof of principle that the immune system can be trained to recognize mutant KRAS before pancreatic cancer becomes clinically apparent.
Learn more
Integrated drug substance manufacturing for global biosimilar programs
In the coming years, more and more biologics will lose exclusivity. Global biosimilar programs could create more affordable alternatives to original therapies. This is a space where European biotech thrives.
Learn more
Mabion Biologics at BIO International Convention 2026
Mabion concluded a highly successful week at the BIO International Convention 2026. Our team engaged in a significant volume of productive meetings, successfully establishing new business relationships.
Learn more
MabionCD20 – Unlocking New Opportunities
MabionCD20 is a anti-CD20 monoclonal antibody originally developed as a biosimilar drug. The project is now being reactivated as an innovative drug, shifting away from the crowded biosimilar market. MabionCD20 already has two orphan drug designations with the potential to pursue further ODD opportunities thanks to Oddifact partnership.
Learn more